- 抑制劑
- 化合物庫
- 抗體
- 生物試劑
- 新產(chǎn)品
- 聯(lián)系我們
Ganetespib (STA-9090)是一種HSP90抑制劑,在OSA 8種細胞中IC50為4 nM,誘導OSA細胞凋亡,而不影響正常的成骨細胞;是STA-1474的活性代謝物。Phase 3。
Ganetespib (STA-9090) Chemical Structure
CAS: 888216-25-9
細胞系 | 實驗類型 | 給藥濃度 | 孵育時間 | 活性描述 | 文獻信息 |
---|---|---|---|---|---|
A1847 | Apoptosis Assay | 10-100 nM | 24/48/72 h | induces apoptosis time and dose dependently | 23900136 |
H2228 | Cell Viability Assay | 0-1000 nM | 72 h | IC50=13 nM | 23533265 |
H3122 | Cell Viability Assay | 0-1000 nM | 72 h | IC50=10 nM | 23533265 |
K008 | Function Assay | 250 nM | 24 h | induces G2 arrest | 23418523 |
K028 | Function Assay | 250 nM | 24 h | induces G2 arrest | 23418523 |
K029 | Function Assay | 250 nM | 24 h | induces G1 arrest | 23418523 |
M23 | Function Assay | 250 nM | 24 h | induces G1 and G2/M arrest | 23418523 |
K033 | Function Assay | 250 nM | 24 h | induces a modest increase in G1 population | 23418523 |
K008 | Apoptosis Assay | 100 nM | 72 h | significantly induces apoptosis | 23418523 |
K028 | Apoptosis Assay | 100 nM | 72 h | significantly induces apoptosis | 23418523 |
K029 | Apoptosis Assay | 100 nM | 72 h | significantly induces apoptosis | 23418523 |
M23 | Apoptosis Assay | 100 nM | 72 h | significantly induces apoptosis | 23418523 |
K033 | Apoptosis Assay | 100 nM | 72 h | significantly induces apoptosis | 23418523 |
OVCAR-8 | Apoptosis Assay | 10-100 nM | 24/48/72 h | induces apoptosis time and dose dependently | 23900136 |
OVCAR-5 | Apoptosis Assay | 10-100 nM | 24/48/72 h | induces apoptosis time and dose dependently | 23900136 |
SKOV-3 | Cell Viability Assay | 0-1000 nM | 72 h | inhibits cell viability dose dependently | 23900136 |
A1847 | Cell Viability Assay | 0-1000 nM | 72 h | inhibits cell viability dose dependently | 23900136 |
OVCAR-8 | Cell Viability Assay | 0-1000 nM | 72 h | inhibits cell viability dose dependently | 23900136 |
OVCAR-5 | Cell Viability Assay | 0-1000 nM | 72 h | inhibits cell viability dose dependently | 23900136 |
H146? | Function Assay | 30 nM | 72 h | induces persistent G2/M phase arrest | 24166505 |
GLC4 | Function Assay | 30 nM | 72 h | induces persistent G2/M phase arrest | 24166505 |
H82 | Function Assay | 30 nM | 72 h | induces persistent G2/M phase arrest | 24166505 |
MDA-MB-231 | Function Assay | 100 nM | 24 h | inhibits the migratory and invasive capacity? | 24173541 |
BT-20? | Function Assay | 100/250 nM | 24 h | resulted in a dose-dependent destabilization of EGFR, IGF-IR, MET, and CRAF | 24173541 |
MDA-MB-435 | Function Assay | 100 nM | 30 min | inhibits accumulation of HIF-1α | 24248265 |
MDA-MB-231 | Function Assay | 100 nM | 30 min | inhibits accumulation of HIF-1α | 24248265 |
CAL27 | Cytoxicity Assay | 10/50 nM | 24 h | decreases cell proliferation dose dependently | 25205430 |
Detroit562 | Cytoxicity Assay | 10/50 nM | 24 h | decreases cell proliferation dose dependently | 25205430 |
FUDA | Cytoxicity Assay | 10/50 nM | 24 h | decreases cell proliferation dose dependently | 25205430 |
SCC25 | Cytoxicity Assay | 10/50 nM | 24 h | decreases cell proliferation dose dependently | 25205430 |
HT-29 | Function Assay | 50nM | 24 h | induced G0/G1 arrest | 25210794 |
HCT-116 | Function Assay | 50nM | 24 h | induced G0/G1 arrest | 25210794 |
MGC-803 | Function Assay | 0.1-1000 nM | 24 h | induces G2/M cell-cycle arrest | 25590805 |
MKN-28 | Cell Viability Assay | 0.1-1000 nM | 72 h | inhibits cell viability dose dependently | 25590805 |
SGC-7901 | Cell Viability Assay | 0.1-1000 nM | 72 h | inhibits cell viability dose dependently | 25590805 |
MGC-803 | Cell Viability Assay | 0.1-1000 nM | 72 h | inhibits cell viability dose dependently | 25590805 |
MV411 | Apoptosis Assay | 30/80/150/250 nM | 24/48/72 h | induces dose dependant induction of apoptosis | 25882550 |
HL60 | Apoptosis Assay | 30/80/150/250 nM | 24/48/72 h | induces dose dependant induction of apoptosis | 25882550 |
NCI-H1975 | Growth Inhibition Assay | 48 h | IC50=16 nM | 22144665 | |
NCI-H1975 | Growth Inhibition Assay | 72 h | IC50=8 nM | 22144665 | |
K008 | Cell Viability Assay | IC50=60 nM | 23418523 | ||
K028 | Cell Viability Assay | IC50=84 nM | 23418523 | ||
K029 | Cell Viability Assay | IC50=46 nM | 23418523 | ||
M23 | Cell Viability Assay | IC50=37.5 nM | 23418523 | ||
K033 | Cell Viability Assay | IC50=75.5 nM | 23418523 | ||
RD | Growth Inhibition Assay | IC50=8 nM | 23303741 | ||
Rh41 | Growth Inhibition Assay | IC50=10.4 nM | 23303741 | ||
Rh18 | Growth Inhibition Assay | IC50=6.2 nM | 23303741 | ||
Rh30 | Growth Inhibition Assay | IC50=5.6 nM | 23303741 | ||
BT-12 | Growth Inhibition Assay | IC50=14.3 nM | 23303741 | ||
CHLA-266 | Growth Inhibition Assay | IC50=27.1 nM | 23303741 | ||
TC-71 | Growth Inhibition Assay | IC50=4.5 nM | 23303741 | ||
CHLA-9 | Growth Inhibition Assay | IC50=4.6 nM | 23303741 | ||
CHLA-10 | Growth Inhibition Assay | IC50=5.7 nM | 23303741 | ||
CHLA-258 | Growth Inhibition Assay | IC50=6.4 nM | 23303741 | ||
SJ-GBM2 | Growth Inhibition Assay | IC50=12.9 nM | 23303741 | ||
NB-1643 | Growth Inhibition Assay | IC50=7.4 nM | 23303741 | ||
NB-EBc1 | Growth Inhibition Assay | IC50=16.8 nM | 23303741 | ||
CHLA-90 | Growth Inhibition Assay | IC50=22.3 nM | 23303741 | ||
CHLA-136 | Growth Inhibition Assay | IC50=23.2 nM | 23303741 | ||
NALM-6 | Growth Inhibition Assay | IC50=11.7 nM | 23303741 | ||
COG-LL-317 | Growth Inhibition Assay | IC50=4.4 nM | 23303741 | ||
RS4;11 | Growth Inhibition Assay | IC50=13.5 nM | 23303741 | ||
MOLT-4 | Growth Inhibition Assay | IC50=10.6 nM | 23303741 | ||
CCRF-CEM (1) | Growth Inhibition Assay | IC50=12.5 nM | 23303741 | ||
CCRF-CEM (2) | Growth Inhibition Assay | IC50=7.2 nM | 23303741 | ||
Kasumi-1 | Growth Inhibition Assay | IC50=5.8 nM | 23303741 | ||
Karpas-299 | Growth Inhibition Assay | IC50=9.6 nM | 23303741 | ||
Ramos-RA1 | Growth Inhibition Assay | IC50=7.4 nM | 23303741 | ||
LNCaP | Growth Inhibition Assay | IC50=8 nM | 23152004 | ||
VCaP | Growth Inhibition Assay | IC50=7 nM | 23152004 | ||
H1355 | Growth Inhibition Assay | IC50=5 nM | 23012248 | ||
H157 | Growth Inhibition Assay | IC50=7 nM | 23012248 | ||
H460 | Growth Inhibition Assay | IC50=8 nM | 23012248 | ||
IA-LM | Growth Inhibition Assay | IC50=10 nM | 23012248 | ||
HOP-62 | Growth Inhibition Assay | IC50=11 nM | 23012248 | ||
H23 | Growth Inhibition Assay | IC50=11 nM | 23012248 | ||
H2030 | Growth Inhibition Assay | IC50=12 nM | 23012248 | ||
H441 | Growth Inhibition Assay | IC50=14 nM | 23012248 | ||
H2212 | Growth Inhibition Assay | IC50=17 nM | 23012248 | ||
SK-LU-1 | Growth Inhibition Assay | IC50=18 nM | 23012248 | ||
H2009 | Growth Inhibition Assay | IC50=19 nM | 23012248 | ||
H1792 | Growth Inhibition Assay | IC50=20 nM | 23012248 | ||
COR-L23 | Growth Inhibition Assay | IC50=22 nM | 23012248 | ||
H727 | Growth Inhibition Assay | IC50=28 nM | 23012248 | ||
H1734 | Growth Inhibition Assay | IC50=28 nM | 23012248 | ||
H358 | Growth Inhibition Assay | IC50=29 nM | 23012248 | ||
A549 | Growth Inhibition Assay | IC50=43 nM | 23012248 | ||
H2122 | Growth Inhibition Assay | IC50=53 nM | 23012248 | ||
Calu-1 | Growth Inhibition Assay | IC50=58 nM | 23012248 | ||
Calu-6 | Growth Inhibition Assay | IC50=64 nM | 23012248 | ||
AC3 | Growth Inhibition Assay | IC50=25.9 nM | 24166505 | ||
H1173 | Growth Inhibition Assay | IC50=12.62 nM | 24166505 | ||
H792 | Growth Inhibition Assay | IC50=45.07 nM | 24166505 | ||
H620 | Growth Inhibition Assay | IC50=32.67 nM | 24166505 | ||
N592 | Growth Inhibition Assay | IC50=14.12 nM | 24166505 | ||
H526 | Growth Inhibition Assay | IC50=21.64 nM | 24166505 | ||
H187 | Growth Inhibition Assay | IC50=24.99 nM | 24166505 | ||
H146 | Growth Inhibition Assay | IC50=28.51 nM | 24166505 | ||
H128 | Growth Inhibition Assay | IC50=69.55 nM | 24166505 | ||
H69 | Growth Inhibition Assay | IC50=83.36 nM | 24166505 | ||
GLC4 | Growth Inhibition Assay | IC50=20.47 nM | 24166505 | ||
H82 | Growth Inhibition Assay | IC50=30.27 nM | 24166505 | ||
HCC2998 | Growth Inhibition Assay | IC50=128 nM | 24682747 | ||
SK-CO-1 | Growth Inhibition Assay | IC50=81 nM | 24682747 | ||
LS-123 | Growth Inhibition Assay | IC50=73 nM | 24682747 | ||
SNU-C2B | Growth Inhibition Assay | IC50=45 nM | 24682747 | ||
LS-1034 | Growth Inhibition Assay | IC50=31 nM | 24682747 | ||
LoVo | Growth Inhibition Assay | IC50=22 nM | 24682747 | ||
COLO-678 | Growth Inhibition Assay | IC50=21 nM | 24682747 | ||
NCI-H747 | Growth Inhibition Assay | IC50=17 nM | 24682747 | ||
COLO-205 | Growth Inhibition Assay | IC50=14 nM | 24682747 | ||
HCT 116 | Growth Inhibition Assay | IC50=14 nM | 24682747 | ||
HuTu-80 | Growth Inhibition Assay | IC50=13 nM | 24682747 | ||
HCT-15 | Growth Inhibition Assay | IC50=8 nM | 24682747 | ||
SW620 | Growth Inhibition Assay | IC50=8 nM | 24682747 | ||
LS-411?N | Growth Inhibition Assay | IC50=5 nM | 24682747 | ||
RKO | Growth Inhibition Assay | IC50=4 nM | 24682747 | ||
SW780 | Growth Inhibition Assay | IC50=3451 nM | 24784839 | ||
RT4 | Growth Inhibition Assay | IC50=1733 nM | 24784839 | ||
TCCSUP | Growth Inhibition Assay | IC50=142 nM | 24784839 | ||
MGH-U3 | Growth Inhibition Assay | IC50=53 nM | 24784839 | ||
HT-1197 | Growth Inhibition Assay | IC50=53 nM | 24784839 | ||
5637 | Growth Inhibition Assay | IC50=44 nM | 24784839 | ||
35612 | Growth Inhibition Assay | IC50=38 nM | 24784839 | ||
KU-19-19 | Growth Inhibition Assay | IC50=36 nM | 24784839 | ||
LB831-BLC | Growth Inhibition Assay | IC50=34 nM | 24784839 | ||
UM-UC3 | Growth Inhibition Assay | IC50=33 nM | 24784839 | ||
647-V | Growth Inhibition Assay | IC50=27 nM | 24784839 | ||
HT-1376 | Growth Inhibition Assay | IC50=21 nM | 24784839 | ||
J82 | Growth Inhibition Assay | IC50=18 nM | 24784839 | ||
BFTC | Growth Inhibition Assay | IC50=17 nM | 24784839 | ||
SCaBER | Growth Inhibition Assay | IC50=10 nM | 24784839 | ||
639-V | Growth Inhibition Assay | IC50=10 nM | 24784839 | ||
RT112 | Growth Inhibition Assay | IC50=9 nM | 24784839 | ||
T24 | Growth Inhibition Assay | IC50=7 nM | 24784839 | ||
SW-1710 | Growth Inhibition Assay | IC50=6 nM | 24784839 | ||
DSH1 | Growth Inhibition Assay | IC50=6 nM | 24784839 | ||
TC32 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 29435139 | ||
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 29435139 | ||
Saos-2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 29435139 | ||
BT-37 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 29435139 | ||
RD | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 29435139 | ||
SK-N-SH | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 29435139 | ||
NB1643 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 29435139 | ||
OHS-50 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 29435139 | ||
A673 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 29435139 | ||
SJ-GBM2 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 29435139 | ||
SK-N-MC | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 29435139 | ||
NB-EBc1 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 29435139 | ||
LAN-5 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 29435139 | ||
Rh18 | qHTS assay | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 29435139 | ||
點擊查看更多細胞系數(shù)據(jù) |
產(chǎn)品描述 | Ganetespib (STA-9090)是一種HSP90抑制劑,在OSA 8種細胞中IC50為4 nM,誘導OSA細胞凋亡,而不影響正常的成骨細胞;是STA-1474的活性代謝物。Phase 3。 | ||
---|---|---|---|
靶點 |
|
體外研究(In Vitro) | ||||
體外研究活性 | Ganetespib對惡性肥大細胞系的50%抑制濃度(IC50)比對17-AAG低10-15倍,表明三唑酮類HSP90抑制劑可能比格爾德霉素類抑制劑具有更高的效能。[1] Ganetespib抑制MG63細胞系,IC50為43 nM。[1] Ganetespib結(jié)合于Hsp90的N末端ATP結(jié)合域,通過引起多重致瘤性Hsp90受體蛋白,包括HER2/neu,突變型EGFR,Akt,c-Kit,IGF-1R,PDGFRα,Jak1,Jak2,STAT3,STAT5,HIF-1α,CDC2和c-Met 以及Wilms' tumor 1的降解,成為一種有效的Hsp90的抑制劑。[2] Ganetespib,在納摩爾級低濃度下,有效阻滯細胞增殖,并誘導廣泛的人腫瘤細胞系凋亡,并且對許多受體酪氨酸激酶抑制劑-和tanespimycin-耐受的細胞系也具有作用。Ganetespib在一系列固體和血液腫瘤細胞系,包括那些對小分子酪氨酸激酶抑制劑耐受的表達突變激酶的細胞系,都表現(xiàn)出有效的細胞毒性。[3] Ganetespib治療快速引起已知的Hsp90受體蛋白降解,表現(xiàn)出高于ansamycin抑制劑17-AAG的效能,并且在較短的暴露時間下也具有持續(xù)的活性。[3]在另一個研究中,Ganetespib誘導惡性犬肥大細胞系凋亡。Ganetespib在非常低的濃度下,有效作用于C2和BR犬惡性肥大細胞,IC50分別為19和4 nM,而17-AAG抑制C2和BR犬惡性肥大細胞的IC50分別為958和44 nM。[4]100 nM Ganetespib處理24小時后,所有處理過的細胞系,包括C2和BMCMCs細胞中WT和突變型Kit的表達被下調(diào)。然而,Ganetespib處理后不影響PI3K或HSP90的表達。[4] | |||
---|---|---|---|---|
細胞實驗 | 細胞系 | OSA細胞 | ||
濃度 | 0.001-1μM | |||
孵育時間 | 5天 | |||
方法 | 將1.5 × 103 OSA細胞接種于96孔板,在包含10%血清的完全培養(yǎng)基中培養(yǎng)過夜,以測定50%抑制濃度。板在第5天采集,隨后用0.001,0.005,0.01,0.05,0.1,0.5和1 μM Ganetespib處理并分析。熒光測量使用酶標儀在485 nm激發(fā)波長和530 nm發(fā)射檢測波長下進行。相對細胞數(shù)以對照孔的百分比計算:樣品吸光度/DMSO處理的細胞吸光度× 100。 | |||
實驗圖片 | 檢測方法 | 檢測指標 | 實驗圖片 | PMID |
Western blot |
EGFR / c-Met / IGF-1Rβ/ Akt / p-Akt / ERK / p-ERK
感谢您访问我们的网站,您可能还对以下资源感兴趣: 成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天 |